Qbic Fund | Venture Capital
Sara Vandenwijngaert is a professional with a background in biomedical sciences and extensive experience in both research and venture capital. Currently serving as a Junior Partner and Investment Manager at Qbic Fund, Sara is involved in investing in seed and early-stage ventures. Sara also holds board positions at Tanai Therapeutics, ABSCINT, and THERAtRAME, and previously served as an Associate Director at Medpace. With a Ph.D. in Biomedical Sciences from KU Leuven, Sara has also worked as an Instructor at Harvard Medical School and conducted postdoctoral research at Harvard Medical School and Massachusetts General Hospital.
This person is not in any teams
Qbic Fund | Venture Capital
Qbic is a seed and early-stage venture capital fund supporting spin-offs and start-ups that valorize research from Qbic's knowledge partners. Qbic is one of the largest spin-off funds in Europe managing €190 million in resources over the different funds. Qbic I launched in 2012 and has finalized its portfolio of 18 ventures; Qbic II launched in 2017 and has a portfolio of 19 ventures, and Qbic III launched in 2022 and is currently building its portfolio.